UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Opicapone for the Treatment of Parkinson's Disease: a Review of a New Licensed Medicine

Fabbri, M; Ferreira, JJ; Lees, A; Stocchi, F; Poewe, W; Tolosa, E; Rascol, O; (2018) Opicapone for the Treatment of Parkinson's Disease: a Review of a New Licensed Medicine. Movement Disorders 10.1002/mds.27475. (In press).

[img] Text
Lees_OPICAPONE.rew.MDJ_5.05.18.clean.version.pdf - Accepted version
Access restricted to UCL open access staff

Download (713kB)

Abstract

Catechol‐O‐methyl transferase inhibitors are currently used as first‐line add‐on therapy to levodopa for the treatment of end‐of‐dose motor fluctuations in Parkinson's disease patients, as they increase levodopa bioavailability. Several factors hamper the use of current available catechol‐O‐methyl transferase inhibitors, that is, the moderate efficacy and multiple dosing for entacapone and the risk of liver toxicity with tolcapone. Opicapone, a new long‐acting, peripherally selective, once‐daily catechol‐O‐methyl transferase inhibitor, was recently licensed in Europe. Two phase 3 double‐blind clinical trials demonstrated opicapone efficacy in reducing OFF time by an average of about 60 minutes daily compared with placebo, without increasing ON time with troublesome dyskinesias. These effects were also maintained during a subsequent open‐label extension consisting of 1‐year follow‐up. Opicapone showed a good safety profile. From June 2016, Opicapone received the approval for marketing authorization from the European Commission as adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in patients with PD and end‐of‐dose motor fluctuations. We aimed to review the clinical pharmacological data of opicapone, summarize its clinical efficacy and safety issues, and discuss its potential role in the management of Parkinson's disease.

Type: Article
Title: Opicapone for the Treatment of Parkinson's Disease: a Review of a New Licensed Medicine
DOI: 10.1002/mds.27475
Publisher version: https://doi.org/10.1002/mds.27475
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Parkinson's disease, opicapone, COMT inhibitor, motor fluctuations, advanced stage
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Clinical and Movement Neurosciences
URI: https://discovery.ucl.ac.uk/id/eprint/10058616
Downloads since deposit
1Download
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item